Make Informed Investment Decisions with Affordable Access to Experts

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A discussion on lysosomal storage diseases and where Sangamo (SGMO) and Abeona's genetic treatments fit in.

Ticker(s): SGMO, ABEO

Who's the expert?

Name: Blinded Expert

Institution: The Children's Hospital of Philadelphia

  • Associate Professor of Pediatrics and Director of the Newborn Metabolic Screening Program and the Lysosomal Storage Diseases Program at CHOP.
  • Treats over 100 patients with lysosomal storage disorders.
  • His research has resulted in over 65 peer-reviewed journal articles as well as significant contributions to scientific committees, with emphasis on newborn screening and inborn errors of metabolism.

Interview Questions
Q1.

Please describe your current practice. How many patients with lysosomal storage diseases do you currently treat?

Added By: user858a993f
Q2.

Can you please give a short description of MPSI, MPSII and MPSII(a+b) phenotypes and describe the similarities and differences.

Added By: user858a993f
Q3.

How many patients of MPS 1/2/3 there are in US? Which proportion would be considered moderate vs. severe patients? Are these hard populations to identify, and would you consider them  “under-diagnosed” populations?

Added By: user858a993f
Q4.

What types of physicians are treating patients with MPS 1/2/3? How many centers/specialists are in the US? Do you find the parents/patient advocacy groups to be well-organized?

Added By: user858a993f
Q5.

What is the standard of care for each one of the diseases? What % of patients are treated? What would be the reason for patients not to be on the treatment?

Added By: user858a993f
Q6.

What are the unmet needs in those diseases? What would be the top 2-3 things you would like to change with regard to the current standard of care?

Added By: user858a993f
Q7.

How effective is Hematopoietic stem cell transplantation (HSCT) and Enzyme Replacement in each one of those diseases (MPS1/MPS2/MPS3)? What proportion of patients undergo a successful HSCT?

Added By: user858a993f
Q8.

Do you use Enzyme Replacement in patients who were treated with HSCT? If “Yes”, do you experience any "pushback" from payors?

Added By: user858a993f
Q9.

What is the average annual cost of treatment for each one of the diseases? How much does ER and HSCT cost? Do you encounter any problems with payors when prescribing off-label treatment for those patients?

Added By: user858a993f
Q10.

What is your view on the current gene therapy in development from (Abeona) / gene editing (Sangamo) to deal with MPS? What are you most excited about and concerned about for those programs?

Added By: user858a993f
Q11.

How important in your view is the penetration of the enzyme into the CNS?

Added By: user858a993f
Q12.

What is your view on the presented clinical data by Abeona? Is there anything that concerns you in the data? Is it reasonable to expect a higher clinical benefit with constant levels of enzyme in the blood (gene therapy) vs. once a week enzyme replacement with a short T1/2 in the blood?

Added By: user858a993f
Q13.

How problematic is ADA (anti-drug antibodies) in those patients? Which proportion of patients develop ADA?

  • Does it have a negative effect on the effectiveness of the treatment?
  • What application in your view will it have on the gene therapy?
  • Can immune-tolerance be induced in patients with ADA?

Added By: user858a993f
Q14.

If approved and safe in which proportion and what types of patients will the gene therapy be used?  Will it be used before or after the currently approved enzyme replacement/ hematopoietic stem cell transplantation? What is the general view of your colleagues about using gene therapy in those patients?  

Added By: user858a993f
Q15.

Does a $200K-$400K annual price range for a safe and effective treatment (let’s assume more effective than current standard of care) sound reasonable to you?  

Added By: user858a993f
Q16.

Do you anticipate problems with enrollment for those studies? For example, will it be hard to find MPS1 patients which are >18 years old?

Added By: user858a993f
Q17.

Should we anticipate to see therapeutic effect (not only enzyme levels in blood) in adults’ population pre-treated with enzyme replacement therapy (the population which is first to be enrolled into the clinical trials)? Can we potentially anticipate seeing improvement in CNS related symptoms?  

Added By: user858a993f

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.